Converge Bio
Tel Aviv, Israel· Est.
AI‑powered platform that designs and optimizes biologics and targets to speed up early drug discovery.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $25M
AI Company Overview
AI‑powered platform that designs and optimizes biologics and targets to speed up early drug discovery.
OncologyImmunologyProtein Therapeutics
Technology Platform
Generative bio‑LLMs that model DNA, RNA, protein, and cellular phenotypes, combined with binding and developability predictors to design antibodies, optimize gene expression, and discover targets.
Opportunities
Scaling the platform across multiple therapeutic modalities and forming strategic partnerships with pharma to co‑develop AI‑generated biologics.
Risk Factors
Model accuracy and validation in real‑world wet‑lab settings, data‑privacy concerns, and intense competition from other AI drug‑discovery firms.
Competitive Landscape
Competes with Insilico Medicine, Atomwise, Exscientia, and DeepMind’s AlphaFold‑based services, differentiating through a fully managed private cloud and royalty‑free IP ownership.